ArticleClinical ophthalmology (Auckland, N.Z.)2026
Link Between Baseline Peripheral Vascular Leakage and Treatment Response in Patients with Central Retinal Vein Occlusion: A Pilot Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the potential link between quantitative measures of retinovascular function and response to intravitreal bevacizumab in patients with central retinal vein occlusion (CRVO). Patients and Methods: This retrospective, observational cohort study included 28 eyes with CRVO that satisfied the following inclusion criteria: age over 18 years; bevacizumab treatment for at least 4 months; best corrected visual acuity (BCVA) measurements at baseline and post-treatment; and pre-treatment ultra-wide field fluorescein angiography (UWF-FA). The RETICAD software was used for quantitative analysis of baseline UWF-FA, generating measures of blood flow, perfusion, and blood-retina barrier (BRB) in the central and peripheral retina. Responders and non-responders were defined based on BCVA stratification method developed by the DRCR network. Baseline differences between responders and non-responders were assessed using the Wilcoxon Rank Sum test. The discriminative performance of baseline measures in distinguishing responders from non-responders was evaluated using logistic regression. Results: At baseline, responders had significantly higher peripheral leakage (p = 0.034), but not central leakage (p = 0.444), compared to non-responders. No significant baseline differences were observed in perfusion or blood flow. The highest discriminative performance for treatment response was observed for baseline BRB leakage in the nasal-peripheral and inferior-peripheral regions (AUC = 0.77 and 0.75, respectively). Baseline blood flow, perfusion, central macular thickness (CMT), and BCVA demonstrated lower discriminative performance. Conclusion: High peripheral BRB leakage at baseline may be associated with an increased likelihood of benefiting from bevacizumab treatment. While this pilot study highlights the potential of quantitative UWF-FA analysis to guide CRVO therapy, these findings require validation in a larger, prospective, multicenter study with a standardized treatment protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.